
Beryl Manning-Geist, MD
250 posts

Beryl Manning-Geist, MD
@Doctor_Beryl
Emory SOM Faculty | Memorial Sloan Kettering Gynecologic Oncology Fellow | Harvard OB-GYN | Views are my own











.@StephanieVBlank and @DmitriyZamarin head newly-established Center of Excellence for Gynecologic Oncology at @MountSinaiNYC mountsinai.org/about/newsroom… mountsinai.org/care/cancer/se… #GynecologicCancer


#Editorial on #SENECA study @SENECAStudy @ bit.ly/3MA71Fm #SLNmapping #EndometrialCancer @Quique_ChC @ClinicaNavarra @JennyMueller @Doctor_Beryl @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @RParejaGineOnco @lchiv4 @annafagottimd @Frumovitz @HousseinELHAJJ3 @AinhoaMada @Jc_vilches @erodriguezglez @daggezmine @astraubhar #WeeklyPodcast #LeadArticle #IJGConline #Research #Prevention #Treatment #Diagnostic #GynCancer #GynOnc #WomenHealth #SoMe #SoMe4GynOnc




Approximately 40% of ovarian low-grade serous carcinomas (LGSCs) are folate receptor α (FRα)-high. Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities - Gynecologic Oncology gynecologiconcology-online.net/article/S0090-… @gynoncjnls

Wonderful new paper out from @Doctor_Beryl evaluating folate receptor alpha expression in low grade serous ovarian cancer. A biomarker-driven approach to treatment selection is promising. @TeamOvary_MSK @TeamEndo_MSK pubmed.ncbi.nlm.nih.gov/38941962/







‼️ New editorial 📄 program initiative between @gynoncjnls and #BRIDGES 🌉 scholars 👏 @SGO_org @GYNCancer @GOG @David_Cohn_MD @Doctor_Beryl @MMAlHilli @sy_rachel @LAURAJMOULTON @DNasioudis



What role does molecular subtyping play in guiding ovarian preservation in endometrial cancer❓❓Check this highly anticipated podcast by Dr. Mueller and @Doctor_Beryl @MSKCancerCenter #gyncsm #gyn






